{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T21:41:07Z","timestamp":1698010867188},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T00:00:00Z","timestamp":1133827200000},"content-version":"vor","delay-in-days":6183,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[1989,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Horizontal transmission of hepatitis B virus (HBV) from illicit drug users to their contacts, including young children, can be prevented by active immunization against HBV. Yeast\u2010recombinant hepatitis B vaccines are now available for this purpose, but their potential efficacy in such high\u2010risk contacts has not yet been evaluated. Therefore we gave 20 mcg of a recombinant yeast\u2010derived hepatitis B vaccine to 38 children who were at high risk for HBV infection because they had been institutionalized in a community for drug users in which 8.7% of the occupants are carriers. After third dose of vaccine (at 0, 1, and 6 months), all children had anti\u2010HBs responses with titers of 10 mlU\/ml or more, with 81% showing responses greater than 1,000 mlU\/ml. At 12 months, the percentage of anti\u2010HBs\u2010positive children was 100%, and the percentage of children with anti\u2010HBs higher than 1,000 mlU\/ml was 56%. None of the children developed HBV infection during follow\u2010up. Hence the recombinant vaccine was immunogenic, with percentages of seroconversion and anti\u2010HBs titers comparable with those attained in other categories of high\u2010risk children with plasma\u2010derived vaccines.<\/jats:p>","DOI":"10.1002\/jmv.1890270111","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T16:30:39Z","timestamp":1172853039000},"page":"48-51","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity of a yeast\u2010recombinant hepatitis B vaccine in high\u2010risk children"],"prefix":"10.1002","volume":"27","author":[{"given":"M. G.","family":"Rumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bortolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gringeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Zanett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"issue":"2","key":"e_1_2_1_2_1","first-page":"169","article-title":"Summary of clinical findings on Engerix\u2010B, a genetically engineered yeast\u2010derived hepatitis B vaccine","volume":"63","author":"Andr\u00e9 FE","year":"1987","journal-title":"Postgraduate Medical Journal"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90431-9"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6514.159"},{"key":"e_1_2_1_5_1","first-page":"313","article-title":"Recommendations for protection against viral hepatitis","volume":"34","author":"Centers for Disease Control","year":"1985","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"e_1_2_1_6_1","first-page":"354","article-title":"Update on hepatitis B prevention","volume":"36","author":"Centers for Disease Control","year":"1987","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90543-X"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92000-8"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.26.1.4"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607243150401"},{"issue":"2","key":"e_1_2_1_11_1","first-page":"83","article-title":"Immunological properties of recombinant HBsAg produced in yeast","volume":"63","author":"Hauser P","year":"1987","journal-title":"Postgraduate Medical Journal"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.257.19.2634"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92926-X"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92740-5"},{"key":"e_1_2_1_15_1","first-page":"72","volume-title":"Viral infections","author":"Jilg W","year":"1986"},{"key":"e_1_2_1_16_1","unstructured":"JustM ScheiemannN:Persistence of anti\u2010HBs induced by a yeastderived hepatitis B vaccine. (In press.)"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90542-5"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(86)92623-X"},{"key":"e_1_2_1_19_1","first-page":"30","article-title":"Delta agent diffusion in institutionalized Down's syndrome patients","volume":"16","author":"Marinucci G","year":"1984","journal-title":"The Italian Journal of Gastroenterology"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/307178a0"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91171-7"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840040603"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90976-X"},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oxfordjournals.aje.a113533","article-title":"Epidemiologic patterns of infection with the hepatitis B virusassociated delta agent in Italy","volume":"117","author":"Smedile A","year":"1983","journal-title":"American Journal of Epidemiology"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(86)92668-X"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890180405"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6454.1243"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.1890270111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.1890270111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:49:04Z","timestamp":1697935744000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.1890270111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1989,1]]}},"alternative-id":["10.1002\/jmv.1890270111"],"URL":"https:\/\/doi.org\/10.1002\/jmv.1890270111","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1]]}}}